Pelabresib in Myelofibrosis: Exploring Disease Modification and Immune Response
Panelists discuss how myelofibrosis management involves a blend of medications, supportive care, and potential stem cell transplantation, with a focus on Janus kinase inhibitors and investigational agents like pelabresib for modifying disease progression, as well as the findings from the MANIFEST-2 trial regarding spleen volume reduction and biomarker data.
EP. 1: Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making
September 19th 2024Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.
EP. 2: Approved and Investigational Agents for Myelofibrosis
September 19th 2024Panelists discuss how Janus kinase (JAK) inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, as well as investigational agents like pelabresib and navitoclax, target the dysregulated JAK-STAT pathway to manage symptoms and potentially modify disease progression in myelofibrosis.
